UK markets closed

Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
38.97+0.43 (+1.12%)
At close: 04:00PM EDT
38.72 -0.25 (-0.64%)
After hours: 07:54PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 3.44B
Enterprise value 3.09B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)8.04
Enterprise value/revenue N/A
Enterprise value/EBITDA -7.20

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3186.97%
S&P500 52-week change 322.36%
52-week high 362.21
52-week low 312.96
50-day moving average 350.78
200-day moving average 335.27

Share statistics

Avg vol (3-month) 31.31M
Avg vol (10-day) 32.04M
Shares outstanding 588.26M
Implied shares outstanding 688.26M
Float 866.67M
% held by insiders 112.84%
% held by institutions 184.01%
Shares short (15 Apr 2024) 48.91M
Short ratio (15 Apr 2024) 46.64
Short % of float (15 Apr 2024) 412.60%
Short % of shares outstanding (15 Apr 2024) 410.90%
Shares short (prior month 15 Mar 2024) 48.63M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-46.39%
Return on equity (ttm)-84.44%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -429.14M
Net income avi to common (ttm)-408.17M
Diluted EPS (ttm)-5.73
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)381.82M
Total cash per share (mrq)4.68
Total debt (mrq)30.88M
Total debt/equity (mrq)7.21%
Current ratio (mrq)7.98
Book value per share (mrq)5.28

Cash flow statement

Operating cash flow (ttm)-331.72M
Levered free cash flow (ttm)-213.77M